Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XOESP
ADC Name
CA2975383C example21
Synonyms
CA2975383C example21
   Click to Show/Hide
Organization
SORRENTO THERAPEUTICS, INC.
Drug Status
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
undisclosed
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Tubulin inhibitor A
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random coupling of lysine
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.1326
nM
CVCL_0620
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.1788
nM
CVCL_1259
Breast ductal carcinoma
Half Maximal Effective Concentration (EC50) 
0.3432
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.4904
nM
CVCL_1400
Invasive breast carcinoma of no special type
Half Maximal Effective Concentration (EC50) 
1.065
nM
CVCL_0532
Ovarian serous adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.1326 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.1788 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.3432 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.4904 nM Low HER2 expression (HER2+)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Invasive breast carcinoma of no special type MDA-MB-175 cells CVCL_1400
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.065 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Ovarian serous adenocarcinoma SKOV-3 cells CVCL_0532
References
Ref 1 Antibody drug conjugates comprising dolastatin derivatives